This release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. The Company expects to be ready to sell McPulse in the US market during the second half of year 2003. The company also has received FDA approval for the company's other medical health equipment products McPulse, which is used for measurement and analysis of PTG, and APG. The company expects that this opening of the US market for ABR-2000 will result in sales of this product to increase even greater percentage than sales increase over the past quarter. 5 times more unit sales than occurred during the same period of last year. By the end of August 2002, Meridian had sold a total of 197 ABR-2000 units in Korea, 2.
ABR-2000 received FDA approval on August 29 2002.
The device traces autonomic bioelectric responses emanating from different areas of the body. ABR-2000 is an automatic whole body-screening device used to detect stress related problems and to identify that portion of the human body which is experiencing disturbance due to stress.
